Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma

NCT00093080 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00093080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00093080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2004
Completion date
November 30, 2008
Enrollment
216 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma, liposarcoma, metastases, osteosarcoma, sarcoma, soft tissue